NCT01596335View on ClinicalTrials.gov

Clinical Study of TA-650 in Patients With Refractory Kawasaki Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

October 31, 2014

Study Completion Date

October 31, 2014

Conditions
Kawasaki Disease Refractory to Initial Therapy With Intravenous Immunoglobulin
Interventions
DRUG

TA-650

TA-650 at 5 mg per kg body weight on the day of TA-650 administration (day 0) is administered by intravenous infusion slowly over at least 2 hours.

DRUG

Polyethylene Glycol-treated Human Immunoglobulin (VGIH)

VGIH at 2 g per kg body weight on the day of VGIH administration (day 0) is administered by intravenous infusion slowly over at least 20 hours.

Trial Locations (8)

Unknown

Investigational site, Chugoku

Investigational site, Chūbu

Investigational site, Hokkaido

Investigational site, Kanto

Investigational site, Kyushu

Investigational site, Shinetu

Investigational site, Tōhoku

Investigational site, Tōkai

Sponsors
All Listed Sponsors
lead

Mitsubishi Tanabe Pharma Corporation

INDUSTRY